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Abstract: Dietary carotenoids, especially xanthophylls, have attracted significant attention 
because of their characteristic biological activities, including anti-allergic, anti-cancer, and 
anti-obese actions. Although no less than forty carotenoids are ingested under usual dietary 
habits,  only  six  carotenoids  and  their  metabolites  have  been  found  in  human  tissues, 
suggesting  selectivity  in  the  intestinal  absorption  of  carotenoids.  Recently,  facilitated 
diffusion  in  addition  to  simple  diffusion  has  been  reported  to  mediate  the  intestinal 
absorption of carotenoids in mammals. The selective absorption of carotenoids may be 
caused by uptake to the intestinal epithelia by the facilitated diffusion and an unknown 
excretion  to  intestinal  lumen.  It  is  well  known  that  β-carotene  can  be  metabolized  to 
vitamin A after intestinal absorption of carotenoids, but little is known about the metabolic 
transformation  of  non  provitamin  A  xanthophylls.  The  enzymatic  oxidation  of  the 
secondary hydroxyl group leading to keto-carotenoids would occur as a common pathway 
of xanthophyll metabolism in mammals. This paper reviews the absorption and metabolism 
of xanthophylls by introducing recent advances in this field. 
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1. Introduction 
Carotenoids, which are synthesized de novo by microorganisms and plants, accumulate in various 
biological tissues throughout the food chain. More than 700 carotenoids, including the metabolites in 
animals, are present in nature. Most of the carotenoids contain oxygen functions in the molecules, and 
these carotenoids are referred to as xanthophylls. In recent years, a great deal of attention has been 
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focused on biological activities of dietary xanthophylls such as lutein, zeaxanthin, β-cryptoxanthin, 
capsanthin, astaxanthin, and fucoxanthin. 
Lutein is one of the major xanthophylls present in green leafy vegetables. Lutein and zeaxanthin are 
known to selectively accumulate in the macula of the human retina. They have been thought to work as 
antioxidants  [1,2]  and  as  blue  light  filters [3]  to  protect  the  eyes  from  such  oxidative  stresses  as 
cigarette smoking  and  sunlight exposure, which can lead to  age-related macular  degeneration and 
cataracts. β-Cryptoxanthin, a major xanthophyll in fruits such as papaya and mandarin orange, was 
reported to decrease the gene expression of interleukin-1β in mouse macrophage RAW264 cells [4], to 
promote osteoblastic differentiation of mouse MC3T3 cells [5], and to prevent the decrease of calcium 
content in the bone of ovariectomized rat [6]. Capsanthin, a major xanthophyll in paprika, was reported 
to increase high-density lipoprotein (HDL)-cholesterol in rat plasma [7]. 
Astaxanthin and fucoxanthin are abundant in green algae and brown algae, respectively. Numerous 
studies have reported that astaxanthin has the potential to prevent cancers, diabetes, and inflammatory 
and cardiovascular diseases [8,9]. Fucoxanthin has been shown to inhibit the growth of various cancer 
cell lines [10–14] and chemically induced mouse carcinogenesis [15]. Furthermore, the anti-allergic 
and anti-obese activities of fucoxanthin were recently shown in rodent mast cells [16] and in mice [17], 
respectively. Neoxanthin, which has a structure similar to that of fucoxanthin, is present in green leafy 
vegetables.  These  two  xanthophylls  have a  5,6-monoepoxide and an allenic bond as  the common 
characteristic functional groups (Figure 1). We found that fucoxanthin and neoxanthin showed the 
highest  inhibitory  effect  on  the  proliferation  of  human  prostate  cancer  cells  among  the  fifteen 
carotenoids tested [13]. 
Figure 1. Chemical structures of various epoxy xanthophylls. The geometrical configuration 
of neoxanthin in nature was recognized as 9′-cis. 
 
Thus, the characteristic biological activities of several xanthophylls have attracted a great deal of 
attention. Although no less than forty carotenoids are ingested from common foods, only six major 
carotenoids (β-carotene, α-carotene, lycopene, β-cryptoxanthin, lutein, and zeaxanthin), their proposed Mar. Drugs 2011, 9  
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metabolites, and several acyclic carotenes such as phytoene, phytofluene, and δ-carotene have been 
found in the plasma of human subjects under usual dietary habits [18,19]. For example, neoxanthin and 
violaxanthin are ingested together with lutein from green leafy vegetables, but the accumulation of the 
former two xanthophylls was not confirmed in human plasma [18]. Carotenoids are thought to be 
selectively  absorbed  in  the human intestine. Moreover, carotenoid  accumulations in the biological 
tissues are known to differ greatly among animal species [20]. However, the mechanisms underlying 
these phenomena have not been determined. 
After intestinal absorption of dietary carotenoids, conversion from β-carotene to vitamin A is well 
known  in  animals.  In  fishes  and  birds,  oxidative  and  reductive  metabolisms  of  the  end  group  in 
xanthophylls were also proposed by the identification of the metabolic products, but details as to the 
mechanism of their metabolic transformation are yet to be elucidated. In mammals, several proposed 
metabolites  of  xanthophylls  have  been  detected  in  the  tissues,  but  the  metabolic  pathway  is  still 
uncertain. It is necessary to reveal the carotenoid metabolism after intestinal absorption in order to 
elucidate not only the mechanism of the biological activities but also the exact bioavailability. Here, 
we describe the absorption and metabolism of xanthophylls in mammals. 
2. Bioaccessibility of Carotenoids 
Although xanthophylls have the potential to prevent various degenerative diseases  as described 
above,  the  bioavailability  of  carotenoids  is  lower  than  that  of  other  fatty  components  such  as  
α-tocopherol  and  triacylglycerols  [21–24].  The  major  cause  of  the  low  bioavailability  is  the  poor 
solubility of carotenoids in digestive fluid. Carotenoids must be solubilized in the digestive fluid via 
several steps before uptake by intestinal epithelial cells can occur [25]. First, carotenoids are released 
from the food matrix. In some types of food, the matrix interferes with the release of carotenoids. 
Carotenoids are hardly released from raw vegetables due to the solid structure of the cell walls, but 
processing  and  heat  treatment  of  foods  accelerate  the  release  of  carotenoids  by  destroying  the 
structures [26]. The released carotenoids must be well dispersed in the gastrointestinal tract. However, 
the carotenoid dispersion is greatly limited in digestive fluid due to the high hydrophobicity of C40 
isoprenoid carbon skeletons. In this step, dietary lipids facilitate the carotenoid dispersion. Carotenoids 
are dissolved into the dietary lipids and then dispersed as an emulsion in the digestive fluid. The 
digestion of the dietary lipids in the emulsion progresses with the aid of lipolytic enzymes and bile 
fluid, and finally the carotenoids are solubilized in the mixed micelle. The mixed micelle consisting of 
bile acids, phospholipids, cholesterol, fatty  acids, and monoacylglycerols has a disk-like shape, in 
which the outside is surrounded by the bile acids [27]. Carotenoids solubilized in the mixed micelle are 
thought to become accessible to uptake by the intestinal epithelial cells. Thereby, the bioaccessibility is 
defined as the ratio of carotenoids solubilized in the mixed micelles to the total carotenoids ingested. 
The bioaccessibility, dependent on the food matrix, processing, cooking, and structures of carotenoids, 
is an important factor for bioavailability.  
3. Intestinal Absorption of Xanthophylls 
In addition to the bioaccessibility, carotenoid uptake by intestinal epithelial cells is also a critical 
factor for the carotenoid bioavailability. Only one part of the accessible carotenoid is taken up by the Mar. Drugs 2011, 9  
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intestinal epithelial cells and secreted into lymph as chylomicrons for circulating in blood stream. After 
the chylomicrons are degraded by lipoprotein lipase, carotenoids in chylomicron remnants are taken up 
by the liver. The carotenoids are stored in liver or resecreted as very-low-density lipoprotein into the 
blood stream, and then delivered as low-density lipoprotein (LDL). Finally, carotenoids are taken up to 
tissues through the LDL receptor. Highly hydrophobic carotenoids such as β-carotene and lycopene are 
localized in the inner part of LDL, while less hydrophobic xanthophylls such as lutein and zeaxanthin 
are equally distributed to LDL and HDL, and localized in the outer surface area of the lipoprotein 
particles [28]. 
The intestinal absorption of carotenoids had been thought to be mediated by simple diffusion [29,30]. 
To characterize the human intestinal absorption of carotenoids, we compared the uptakes of various 
carotenoids by human intestinal Caco-2 cells [31]. The carotenoids solubilized at the same concentration 
in  mixed  micelles  were  incubated  with  the  Caco-2  cells.  The  uptakes  were  correlated  with  their 
lipophilicity, suggesting that simple diffusion mediated the intestinal uptake of the carotenoids. The 
amounts of fucoxanthin and neoxanthin taken up by the cells were approximately 25% of that of lutein 
and were the lowest among the eleven carotenoids tested. These results indicated that fucoxanthin and 
neoxanthin were certainly absorbed in the Caco-2 cells, although the amounts were lower than that of lutein.  
In addition to the experiments using Caco-2 cells, we were able to confirm the absorption of these 
two  xanthophylls  in  mice  [32–34].  The  xanthophylls  solubilized  in  mixed  micelles  were  orally 
administrated to male ICR mice. Fucoxanthinol and amarouciaxanthin A derived from fucoxanthin 
were detected in plasma and the liver [32,33]. A similar result was also reported in rats fed with 
fucoxanthin [35]. Neoxanthin and neochromes (formed from neoxanthin by intragastric acidity) were 
detected in plasma and the liver [34]. The plasma concentrations in the mice 2 h after administration of 
four purified carotenoids (40 nmol) in the independent experiments under almost the same condition 
were as follows: 36 nM for β-carotene [36]; 10 nM for lutein [36]; 35 nM for neoxanthin (neoxanthin 
and  neochromes)  [34]  and  50  nM  for  fucoxanthin  (fucoxanthinol  and  amarouciaxanthin  A)  [33]. 
Neoxanthin and fucoxanthin were confirmed to be absorbed at a similar level to those of β-carotene 
and lutein, and no selectivity for carotenoids tested was found in mice. 
In addition to rodents, it has been reported that fucoxanthin is absorbed in other animals such as 
tunicates [37,38], chicken [39], and aquatic insects [40]. However, fucoxanthin was not absorbed in 
freshwater fish [40]. East Asian people ingest fucoxanthin from foodstuffs such as sea squirt, sea urchins, 
mussel, and brown algae. However, no information on the absorption of fucoxanthin in humans has been 
available. Although neoxanthin and violaxanthin are ingested from green leafy vegetables under usual 
dietary habits, they were not found in human serum and milk by a detailed analysis of carotenoids [19]. 
Thus, it has been uncertain whether fucoxanthin and neoxanthin are absorbed in humans. 
We reported for the first time the bioavailability of fucoxanthin from edible brown algae (wakame) 
and of neoxanthin and violaxanthin from spinach in humans [41]. After the daily intake of stir-fried 
wakame containing 6.1 mg fucoxanthin for 1 week, the concentrations of fucoxanthin and its metabolites 
in  plasma  were  analyzed  by  HPLC.  Fucoxanthin  and  amarouciaxanthin  A  were  not  detected. 
Fucoxanthinol was detected, but the plasma concentration was under the quantification limit (1.0 nM). 
Similar to the case of fucoxanthin, the plasma concentrations of neoxanthin and violaxanthin after the 
intake of stir-fried spinach were under the quantification limit. On the other hand, both β-carotene and 
lutein, which were present with these epoxy xanthophylls in the same food matrix of spinach, were Mar. Drugs 2011, 9  
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increased in the plasma [41], suggesting that little neoxanthin and violaxanthin in spinach were absorbed 
in humans. In contrast to the case of mice, selective absorption of carotenoids may occur in humans. 
The low bioavailability of these epoxy xanthophylls may be caused by their low bioaccessibility 
from spinach and wakame. However, the bioaccessibility of neoxanthin (neoxanthin and neochromes) 
from spinach was comparable with that of lutein and was greater than that of β-carotene in in vitro 
digestion  study  [34].  Similarly,  the  bioaccessibility  of  fucoxanthin  from  wakame  was  sufficiently  
high [41]. These results suggested that the bioaccessibility was not a limiting factor of the bioavailability.  
The absence of these epoxy xanthophylls in human plasma may be due to the rapid metabolism. 
However, the concentrations of these epoxy xanthophylls and their metabolites in the plasma were 
under the quantification limit even shortly after the intake of spinach and wakame [41], indicating that 
the rapid disappearance might not occur. 
It is possible that the level of these epoxy xanthophylls in plasma were estimated to be low due to 
unknown  metabolic  transformation  such  as  hydrolysis  of  epoxide  or  formation  of  conjugates  by 
detoxification enzymes after the intestinal uptake. For instance, fucoxanthinol 3′-sulphate found in the 
egg yolk of hens fed with seaweed meal [39] might be formed from fucoxanthin in humans.  
The dietary water-soluble fibers, alginates in wakame may be associated with the low bioavailability 
of fucoxanthin from wakame in humans, because dietary water-soluble fibers inhibited the β-carotene 
and lutein uptake by Caco-2 cells [42]. Thus, it is necessary to reveal the bioavailability of isolated 
carotenoid to avoid the influence of the food matrix.  
There are several reports on the bioavailability of epoxy xanthophylls in the purified preparations 
and the oleoresins in human subjects. Oleoresin, which is extracted from plant materials, does not 
contain dietary fibers and any other polar substances. Capsanthin 5,6-epoxide and violaxanthin were 
not detected in chylomicron after ingestion of paprika oleoresin containing these epoxy xanthophylls [43]. 
However, 9-cis zeaxanthin, which was present at a lower amount than epoxy xanthophylls in paprika 
oleoresin, was found in chylomicron [43]. This result suggested that little capsanthin 5,6-epoxide and 
violaxanthin  in  paprika  were  absorbed  in  humans.  Moreover,  after  a  single  oral  dose  of  purified 
violaxanthin or lutein 5,6-epoxide suspended in corn oil, the two epoxy xanthophylls were not detected 
in  the  plasma  [44].  In  contrast,  after  an  oral  dose  of  purified  β-carotene  5,6-epoxide  (9.1  µmol) 
suspended in corn oil, the plasma concentration reached 2.29 µM [45]. Considering these experimental 
results with the oleoresin and purified xanthophylls, little epoxy xanthophylls that have higher polarity 
than β-carotene 5,6-epoxide would be absorbed by humans, consistent with the results of our human study 
using spinach and wakame. The chemical structures of these epoxy xanthophylls are shown in Figure 1. 
To summarize the intestinal absorption of carotenoids, little of highly polar epoxy xanthophylls such 
as neoxanthin and violaxanthin were absorbed in humans independent of the food matrix. Fucoxanthin 
was absorbed in mice and several other animals, but not in humans and freshwater fishes. A selective 
absorption mechanism for carotenoids would be present in humans, but not in mice. Moreover, the 
selectivity in the intestinal absorption of carotenoids appears to differ among animal species. 
4. Mechanisms of the Intestinal Absorption 
The selective absorption for carotenoids in humans cannot be explained by the simple diffusion 
mechanism alone. On the other hand, recent studies have suggested that the carotenoid uptake is partly Mar. Drugs 2011, 9  
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mediated by facilitated diffusion [46–53]. For example, the ratio of the uptake mediated by scavenger 
receptor class B type 1 (SR-B1) to the total uptake of carotenoids in Caco-2 cells was as follows:  
50% for β-carotene; 20% for β-cryptoxanthin and 7% for lutein/zeaxanthin [53]. The efficiency of  
β-carotene  absorption  was  remarkably  reduced  in  SR-B1  knockout  mice  [54].  The  physiological 
relevance of SR-B1 as an mediator of intestinal uptake for provitamin A carotenoids was indicated  
by the report that retinoic acid and the intestinal transcription factor ISX regulated expressions of  
both  SR-B1  and  β-carotene-15,15′-oxygenase  (BCO1),  an  enzyme  responsible  for  vitamin  A 
production [55]. The facilitated diffusion may cause the selective absorption of carotenoids in humans. 
However, even if SR-B1 does not mediate intestinal uptake of the highly polar epoxy xanthophylls, 
they can pass across membranes via the simple diffusion pathway. Thus, these absorption mechanisms 
could not account for the strict selectivity that was observed in humans. The strict selective absorption 
might occur if most parts of the highly polar epoxy xanthophylls taken up by intestinal epithelial cells 
were excreted back into intestinal lumen.  
The  ATP-binding  cassette  (ABC) transporters such  as ABCG5  and ABCG8 are well known  to 
mediate the excretion of dietary phytosterols [56,57]. Although phytosterols such as β-sitosterol and 
campesterol are ingested from vegetables, grains, and cooking oils, the serum concentrations of the 
phytosterols  are  much  lower  than  that  of  cholesterol  in  mammals  [56,57].  Interestingly,  ABCG5 
polymorphism  was  suggested  to  be  associated  with  the  lutein  bioavailability  from  egg  in  human 
subjects [58]. ABCG5 may excrete lutein and highly polar epoxy xanthophylls to intestinal lumen.  
Figure 2. Proposed mechanisms of selectivity in the intestinal absorption of the dietary carotenoids. 
 
Multi-drug resistance 1 (MDR1, ABCB1) is well known as a major efflux pump for lipid-soluble 
compounds.  As  the  affinity  of  substrates  for  MDR1  has  been  suggested  to  be  related  to  their  
polarity [59], the highly polar xanthophylls may be excreted by MDR1. Carotenoids were evaluated Mar. Drugs 2011, 9  
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for a substrate of MDR1 expressed in certain cancer cells. Neoxanthin and violaxanthin, compared 
with  other  carotenoids  tested,  showed  higher  affinity  for  transfected-human  MDR1  in  mouse 
lymphoma L1210 cells [60], but similar results were not found in several human breast and colon 
cancer  cell  lines  [61,62].  Further  study  is  required  to  confirm  the  involvement  of  MDR1  in  the 
excretion  of  carotenoids  in  intestinal  cells.  Thus,  the  selectivity  in  the  intestinal  absorption  of 
carotenoids  in  humans  is  likely to  be  caused by  these proteins that  mediate uptake and  excretion 
(Figure 2). The specificity of these proteins would cause the differences in the intestinal absorption of 
carotenoids among animal species.  
5. Metabolism of Xanthophylls in Mammals 
It  is  necessary  to  explore  the  metabolism  of  carotenoids  after  intestinal  absorption  in  order  to 
elucidate the mechanism of their biological activities, and to achieve safe and effective applications to 
human subjects. Although β-carotene is known to be metabolized to vitamin A through action of BCO1, 
little is known about the metabolic transformation of non provitamin A xanthophylls in mammals.  
Recently,  we  obtained  evidence  that  the  oxidative  transformation  of  fucoxanthin  and  lutein  to  
keto-carotenoids occurred  in mammals. Fucoxanthinol and amarouciaxanthin A were  found in the 
plasma and liver of mice fed with fucoxanthin, whereas fucoxanthin itself was not detected [32,33]. 
Fucoxanthinol was hydrolyzed from fucoxanthin in the intestinal tract, circulated in the body, and  
then oxidatively converted into amarouciaxanthin A (Figure 3). The conversion of fucoxanthinol into 
amarouciaxanthin A was also found to occur in human hepatoma HepG2 cells. Moreover, we found for 
the first time that the oxidative conversion was mediated in mouse liver microsomal fractions and 
required NAD
+ as a cofactor, demonstrating the metabolic conversion of the 3-hydroxyl end group in 
xanthophylls at the level of enzyme reaction in animals [33].  
Figure 3. Proposed metabolic transformation of fucoxanthin. 
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Several proposed metabolites of lutein, as shown in Figure 4, were previously known to be present 
in such human tissues as plasma, milk, liver, and retina [18,63–66]. Moreover, we found a remarkable 
accumulation  of metabolites  in mice  fed  with lutein [67]. 3′-Hydroxy-ε,ε-caroten-3-one and  lutein 
were  the  predominant  carotenoids  in  the  plasma,  liver,  kidney,  and  adipose,  accompanied  by  
ε,ε-carotene-3,3′-dione, indicating that mice actively convert lutein to keto-carotenoids by oxidizing 
the  secondary  hydroxyl  group.  However,  3-hydroxy-β,ε-caroten-3′-one  (3′-oxolutein),  the  major 
metabolite of lutein in human plasma [67] and the retina [64], was not detected in the tissues of the mice. 
Figure 4. Chemical structures of lutein and its metabolites. 
 
These  metabolites  would  be  formed  by  the  same  enzyme  that  mediated  the  conversion  of 
fucoxanthinol to amarouciaxanthin A. The combined level of the lutein metabolites in the liver of the 
mice was 72.4% of the total (intact lutein and the metabolites) [67]. This indicates that quantification 
of the metabolites is necessary to estimate the lutein bioavailability. Moreover, intact lutein and the 
metabolites may differ in their biological activities. Differences among lutein and its metabolites as 
antioxidants and blue light filters deserved further study. 
Similar  to  the  case  of  lutein  in  mice,  the  oxidative  metabolism  of  the  other  xanthophylls  was 
reported to occur in human subjects. After the ingestion of paprika juice containing capsanthin as a 
major xanthophyll, capsanthon in addition to capsanthin was found in the plasma [68]. Capsanthon 
may be formed from capsanthin by the oxidation of the 3′-hydroxyl group to the 3′-keto group. After 
an oral dose of 4,4′-dimethoxy-β-carotene in peanut oil, both 4-keto-β-carotene and canthaxanthin 
were found in the plasma [69]. These studies certainly indicate that humans have potential metabolic 
activity for the oxidation of secondary hydroxyl groups in various xanthophylls.  
In human tissues, other metabolites of lutein were detected. 3′-Epilutein might be formed by a back 
reduction of 3′-oxolutein that was produced from lutein [64]. meso-Zeaxanthin, which is detected in 
the retina only, might be formed by double bond migration from lutein [64]. The dehydration products 
of lutein, 3-hydroxy-3′,4′-didehydro-β,γ-carotene and 3-hydroxy-2′,3′-didehydro-β,ε-carotene [19] were 
thought to be formed non-enzymatically under acidic conditions of stomach [70,71]. 
Recent studies have indicated the cleavage reaction of xanthophylls occurred in mammals. BCO1 
catalyzes the central cleavage of provitamin A carotenoids, while β-carotene 9′,10′-oxygenase (BCO2) 
expressed  in  vitro  can  cleave  a  double  bond  at  C-9′  and  C-10′  of  β-carotene,  lycopene  and  
xanthopylls  [72–74].  Nonsense  mutation  of  BCO2  was  found  to  be  associated  with  a  yellow  fat 
phenotype  in  sheep,  in  which  xanthophylls  were  accumulated  in  adipose  tissues  [75].  The  BCO2 Mar. Drugs 2011, 9  
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knockout  mice  fed  with  lutein  remarkably  accumulated  lutein  metabolites,  compared  with  the  
wild-type mice [76]. BCO2 might reduce the accumulation of xanthophylls by converting to smaller 
molecules, although the cleavage products and their further metabolites have not been detected in 
animal tissues yet. Thus, in addition to oxidation of secondary hydroxyl group in xanthophylls, the 
cleavage reaction of carbon skeleton by BCO2 would be also a major metabolic transformation of 
xanthophylls in mammals. 
6. Conclusions 
Various carotenoids, in particular, xanthophylls are ingested under usual dietary habits. However, 
carotenoids  accumulated  in  human  tissues  are  limited,  suggesting  selectivity  in  the  intestinal 
absorption and different metabolic fates of carotenoids. The responses to the feeding of highly polar 
xanthophylls indicated that, for humans, intestinal absorption would be strictly selective in comparison 
with mice. The selectivity and its differences among animal species cannot be explained by simple 
diffusion  mechanism  alone.  Instead,  facilitated  diffusion  via  SR-B1  and  an  unknown  excretion  to 
luminal side might cause the selectivity. After intestinal absorption of xanthophylls, the enzymatic 
oxidation of the secondary hydroxyl  group leading to keto-carotenoids would occur as a common 
pathway of xanthophyll metabolism in mammals. We have no knowledge about the relation of these 
metabolites to the biological activities of parental xanthophylls. The potential biological activities of 
xanthophyll metabolites and their further metabolic fates warrant future studies with respect to the 
beneficial effects of xanthophylls on human health. 
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